PIRPHYTO

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Paramount Pharma Private Limited has submitted to the Exchange a copy of disclosure under Regulation 3(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

News Verification : The media had reports that Piramal Life Sciences Limited. may merge with Piramal Healthcare Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Life Sciences Limited has vide its letter inter-alia stated," We would like to state that the Company explores various strategic moves from time to time. However, as a policy and in the interest of its shareholders, the Company does not comment on any report

Paramount Pharma Private Limited has submitted to the Exchange a copy of disclosure under Regulation 3(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated September 20, 2010, titled "Piramal Life Sciences initiates Phase II Trials for P1736-05 for Type II Diabetes in India and Europe".

Piramal Life Sciences Limited has informed the Exchange that the Annual General Meeting of the Company will be held on July 31, 2010. Further, the Register of Members and Share Transfer Books will remain closed from July 26, 2010 to July 31, 2010 (Both days inclusive) for the purpose of Annual General Meeting.

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated March 15, 2010, titled " Piramal Life Sciences Introduces Tinefcon, its Newly Developed Natural Remedy for Psoriasis at American Academy of Dermatology Convention in Miami, USA.". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_PR_15032010.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange that: "The Share Transfer Agent of the Company is being changed from M/s Freedom Registry Limited (formerly known as Amtrac Management Services Limited) to M/s Link Intime India Pvt. Ltd. with effect from 1st February, 2010."

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated September 16, 2009, titled "Piramal Life Sciences makes Presentation on Breakthrough Molecule for Multi Drug Resistant Bacterial Infections at ICAAC Convention in the USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Pira_PR_160909.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated August 25, 2009, titled "Piramal Life Sciences completes Phase I Trials with a New Molecule for Type II Diabetes in Europe". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_PR_25082009.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PIRLIFE_LR_17082009.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange that the Annual General Meeting of the Company will be held on July 14, 2009. Further, the Register of Members and the Share Transfer Books of the Company will remain closed from July 07, 2009 to July 14, 2009 (both days inclusive) in connection with Annual General Meeting.

Piramal Life Sciences Limited has informed the Exchange that: "The name of our Share Transfer Agent has been changed from 'Amtrac Management Services Limited' to 'Freedom Registry Limited' with effect from April 16, 2009".

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated May 20, 2009, titled "Piramal Life Sciences Limited Commences Phase I Trial on New Molecule for Diabetes - Metabolic Syndrome in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PRAMAL_PR_20052009.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange regarding a revised press release. The date of press release should be read as May 13, 2009 instead of May 12, 2009, titled "Piramal Life Sciences receives DCGI Approval to conduct two PhaseI/II Combination Trials of P276 for Pancreatic, and Head and Neck Cancer in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/piramallife_PR_13052009.zip target=NEW> For more

Piramal Life Sciences Limited has informed the Exchange vide its letter dated May 13, 2009 regarding a press release dated May 12, 2009, titled "Piramal Life Sciences receives DCGI Approval to conduct two PhaseI/II Combination Trials of P276 for Pancreatic, and Head and Neck Cancer in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/piramalcare_PR_13052009.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended December 31,2008.A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PIRLIFE_LR_12022009.ZIP target=NEW> For more details click here.</a>

News Verification : The media had reports of a possible takeover of Piramal Life Science Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Piramal Life Sciences Limited has vide its letter inter-alia stated,"The media report about the possible takeover of the company is totally unfounded."

Piramal Life Sciences Limited has informed the Exchange regarding a revised press release dated January 15, 2009, titled "Piramal Life Sciences initiates Phase II trials of P276 for Mantle Cell Lymphoma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PiramalLife_PR_15012009.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated January 15, 2009, titled "Piramal Life Sciences initiates Phase II trials of P276 for Mantle Cell Lymphoma". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PIRLIFE_PR_15012009.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated October 16, 2008, titled "Piramal Life Sciences begins Phase II trial of P276 for head and neck cancer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/PiramalLife_PR_16102008.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated October 13, 2008, titled "Piramal Life Sciences receives DCGI Approval to conduct Phase I Trial of New Cancer Molecule P-1446A-05 in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_PR_13102008.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated September 29, 2008, titled "Piramal Life Sciences obtains approval for Initiation of Phase I Trials of New Cancer Molecule P-1446A-05 in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_PR_29092008.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange that: "At the 7th Annual General Meeting of our Company held on 22nd August, 2008, all the businesses mentioned in the Notice convening the said meeting were transacted and all the resolutions were passed unanimously." A copy of the Notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramallife_not_27082008.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited had informed the Exchange that the Annual General Meeting of the Company would be held on August 07, 2008. The Company has now informed the Exchange that due to unavoidable reasons, the Annual General Meeting of the Company is being rescheduled and Company shall intimate the date for the Annual General Meeting when fixed. However, there is no change in the dates announced for the purpose of Book Closure, which was fixed from July 31, 2008 to August 07, 2008 (both days inclusive). Further, the Company has informed that no dividend is being recommended at the ensuin

Piramal Life Sciences Limited has informed the Exchange that pursuant to the requirements of reg. 13(6) of the SEBI (Prohibition of Insider Trading) Regulations 1992, Company forward herewith the information regarding initial disclosure received under reg. 13(2) from the Promoters/ Directors of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Piramal_Reg_19062008.zip target=NEW> For more details click here.</a>

Piramal Life Sciences Limited has informed the Exchange that the Annual General Meeting of the Company will be held on August 07, 2008. Further, the Register of Members and the Share Transfer Books of the Company will remain closed from July 31, 2008 to August 07, 2008 (both days inclusive) for the purpose of in connection with Annual General Meeting.

News Verification : The media had reports that MPM Capital, Orbimed may buy strategic stake in the company. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Piramal Life Sciences Limited has vide its letter inter-alia stated, "The Company is engaged in New Chemical Entity (NCE) Research and Development Activity, a capital-intensive activity for which company explores from time to time various strategic funding act